Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic Study of Mylan Trastuzumab (Hercules) vs Herceptin
NCT02594761Phase 1Completed
- Sponsor
- Mylan
- Start
- Aug 2013
- Primary completion
- Feb 2014
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
Phase 1, randomised, double-blind trial of narsoplimab in breast cancer and gastric cancer (GC) (3 arms), sponsored by Mylan. Primary endpoints: Peak Plasma Concentration at 71 days, Area Under the Plasma Concentration Versus Time Curve from Time 0 to Last Blood Draw at 71 days and 1 more. Started Aug 2013; status: completed.
02
Drugs
narsoplimab
03
Conditions
breast cancergastric cancer (GC)
Beyond the preview
Go deeper on NCT02594761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02594761.